Similar molecular landscapes for the EGFR network are observed for each cancer type (Figure 1C, Supplementary Table S1) with RAS alterations most common in PAAD (86%), LUAD (39%), and COAD (50%) and PI3K alterations most common in LUSC (55%) and HNSCC (41%). This evidence concerns the gene EGFR and cancer.